Powder: -20°C for 3 years | In solvent: -80°C for 1 year
E6130 may be effective in the treatment of inflammatory bowel disease and is a highly selective CX3CR1 regulator for oral administration.
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
2 mg | ¥ 3,190 | 5日内发货 | ||
5 mg | ¥ 3,730 | 5日内发货 | ||
25 mg | ¥ 13,900 | 8-10周 | ||
50 mg | ¥ 18,300 | 8-10周 | ||
100 mg | ¥ 23,500 | 8-10周 | ||
1 mL * 10 mM (in DMSO) | ¥ 4,570 | 5日内发货 |
产品描述 | E6130 may be effective in the treatment of inflammatory bowel disease and is a highly selective CX3CR1 regulator for oral administration. |
体外活性 | E6130 also shows agonistic activity via CX3CR1 with respect to GTPγS binding (EC50 = 133 nM) and β-arrestin recruitment (EC50 = 2.4 μM) in CX3CR1-expressing CHO-K1 membrane but show no antagonistic activity.E6130 is an orally available and highly selective CX3CR1 modulator, inhibits the fractalkine-induced chemotaxis of human peripheral blood natural killer cells (IC50, 4.9 nM), and down-regulates CX3CR1 on the cell surface of CD56+ NK cells with an EC50 value of 5.2 nM. |
体内活性 | E6130(10 or 30mg /kg, p.o.) reduced some parameters associated with inflammatory bowel disease in a mouse model of CD4+ CD45RBhigh t cell metastatic colitis and a mouse model of oxazolidin-induced colitis. |
分子量 | 556.06 |
分子式 | C28H37ClF3N3O3 |
CAS No. | 1427058-33-0 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 250 mg/mL (449.59 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 1.7984 mL | 8.9918 mL | 17.9837 mL | 44.9592 mL |
5 mM | 0.3597 mL | 1.7984 mL | 3.5967 mL | 8.9918 mL | |
10 mM | 0.1798 mL | 0.8992 mL | 1.7984 mL | 4.4959 mL | |
20 mM | 0.0899 mL | 0.4496 mL | 0.8992 mL | 2.248 mL | |
50 mM | 0.036 mL | 0.1798 mL | 0.3597 mL | 0.8992 mL | |
100 mM | 0.018 mL | 0.0899 mL | 0.1798 mL | 0.4496 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
E6130 1427058-33-0 Autophagy GPCR/G Protein Immunology/Inflammation CXCR E-6130 E 6130 Inhibitor inhibitor inhibit